Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement

Haematologica. 2015 Mar;100(3):e99-101. doi: 10.3324/haematol.2014.114579. Epub 2014 Dec 5.
No abstract available

Keywords: AIEOP; AML; AML1-ETO; CBFB-MYH11; RQ-PCR; RUNX1-RUNX1T1; inv(16); molecular MRD; pediatric; t(8;21).

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Child
  • Child, Preschool
  • Chromosomes, Human, Pair 21*
  • Chromosomes, Human, Pair 8*
  • Core Binding Factor Alpha 2 Subunit / genetics*
  • Cytarabine / therapeutic use
  • Drug Monitoring
  • Etoposide / therapeutic use
  • Female
  • Humans
  • Idarubicin / therapeutic use
  • Induction Chemotherapy / methods
  • Infant
  • Infant, Newborn
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Mutation
  • Neoplasm, Residual
  • Proto-Oncogene Proteins / genetics*
  • RUNX1 Translocation Partner 1 Protein
  • Survival Analysis
  • Transcription Factors / genetics*
  • Translocation, Genetic

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Core Binding Factor Alpha 2 Subunit
  • Proto-Oncogene Proteins
  • RUNX1 Translocation Partner 1 Protein
  • RUNX1 protein, human
  • RUNX1T1 protein, human
  • Transcription Factors
  • Cytarabine
  • Etoposide
  • Idarubicin